PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCedazuridine
Inqovi, Inaqovi(cedazuridine)
Inaqovi, Inqovi (cedazuridine) is a small molecule pharmaceutical. Cedazuridine was first approved as Inqovi on 2020-07-07. It has been approved in Europe to treat myeloid leukemia. It is known to target cytidine deaminase.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Inqovi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cedazuridine
+
Decitabine
Tradename
Company
Number
Date
Products
INQOVITaiho OncologyN-212576 RX2020-07-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
inqoviNew Drug Application2024-11-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myelodysplastic syndromes—D009190D46
Agency Specific
FDA
EMA
Expiration
Code
CEDAZURIDINE / DECITABINE, INQOVI, OTSUKA
2027-07-07ODE-316
2025-07-07NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Cedazuridine / Decitabine, Inqovi, Otsuka
82688002030-08-22DPU-2864, U-2865, U-2866, U-2867
86180752028-10-16U-2864, U-2867
95673632028-10-16DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D462————2
PreleukemiaD011289——2————2
SyndromeD013577——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCedazuridine
INNcedazuridine
Description
Decitabine/cedazuridine, sold under the brand name Inqovi among others, is a fixed-dose combination anticancer medication used for the treatment of adults with myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.
Classification
Small molecule
Drug classantivirals; antineoplastics (uridine derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Identifiers
PDB—
CAS-ID1141397-80-9
RxCUI—
ChEMBL IDCHEMBL3237547
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID39IS23Q1EW (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CDA
CDA
Organism
Homo sapiens
Gene name
CDA
Gene synonyms
CDD
NCBI Gene ID
978
Protein name
cytidine deaminase
Protein synonyms
Cytidine aminohydrolase, cytosine nucleoside deaminase, small cytidine deaminase
Uniprot ID
P32320
Mouse ortholog
Cda (72269)
cytidine deaminase (Q9D7V3)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 395 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,057 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use